EDITOR’S NOTE: Submitted by Lâle White, CEO of XIFIN, Inc., of Carlsbad, California, this letter describes the problems caused by the Medicare program’s failure, as of January 1, 2013, to be ready to process and reimburse lab test claims for more than 100 new molecular diagnostic CPT codes. Dear Editor: Everyone should read Scott Gottlieb, […]
- "Letter to the Editor"
Medicare Taken to Task about Molecular Test Pricing Method
- By Robert Michel
- > From the Volume XX No. 5 - April 15, 2013 Issue
- Tags: acla, american clinical lab, american clinical laboratory, clinical lab, clinical lab fee schedule, clinical laboratories, Clinical Laboratory, cpt, cpt code, diagnostic assays, diagnostic industry, Diagnostic tests, ehi, genetic test, genetic testing, impac, in vitro diagnostic, in vitro diagnostics, lab industry, lab test, laboratories, laboratory association, laboratory coding, laboratory test, laboratory testing, medical diagnostic, medical lab, medical laboratories, Medicare, MolDx, molecular diagnostic, molecular diagnostic test, molecular diagnostic tests, molecular pathology, mopath, quest diagnostics and labcorp, the laboratory, xifin
